✓ Last verified: February 3, 2026 — Edited & verified by Angelica Bottaro for HealingMaps Editorial Staff

Known For: Long-established IV ketamine practice run by a UPenn-affiliated psychiatrist with over 15 years of experience treating depression in Philadelphia.
| Google Reviews | 4.5/5 (31 reviews) |
| Location | Philadelphia, PA (Fairmount area) |
| Address | 2401 Pennsylvania Avenue, #1C44-45, Philadelphia, PA 19130 |
| Phone | 267-727-2121 |
| Website | ketamineofphiladelphia.com |
| Treatments | IV Ketamine Infusion |
| Conditions Treated | Depression, Chronic Depression, Treatment-Resistant Depression |
| Cost | ~$3,000 for 6 infusions (contact for current pricing) |
| Insurance | Private pay only; insurance does not cover ketamine infusions |
| KAP Available? | IV infusion protocol (not psychotherapy-assisted) |
| Clinical Lead | John Applegate, MD (Board-Certified Psychiatrist, UPenn-affiliated) |
HealingMaps Take: Dr. Applegate’s long tenure at UPenn and 15+ years of psychiatric experience bring a level of clinical credibility that few ketamine clinics can match. The standard 6-infusion protocol over 2–3 weeks follows established research guidelines. While pricing sits at the higher end for Philadelphia, the medical oversight here is top-tier.
Market Position: Ketamine of Philadelphia is an IV-ketamine-focused clinic in the Philadelphia metro — the most common cash-pay protocol in the HealingMaps verified directory.
Industry pricing reference. Ketamine of Philadelphia has not published specific per-session pricing — contact the clinic directly for a quote. The calculator above shows typical metro-level cost estimates across protocols, not this clinic’s specific prices.
| Protocol | Typical Industry Cost | Offered Here |
|---|---|---|
| IV Ketamine | $350–$650/session | ✓ Yes |
| Spravato (esketamine) | $0–$250 copay (insured) | — |
| IM Ketamine | $250–$400/injection | — |
| KAP (with therapist) | $400–$1,200/session | — |
| At-home troches | $150–$300/month | — |
Sources: CDC PLACES 2023 (Pennsylvania, state-level prevalence) · U.S. Census ACS 5 Year · HealingMaps proprietary patient inquiry data.
Behind this data: HealingMaps has analyzed 23,496 patient inquiries (Oct 2022 – Mar 2026), mapped 1,473 verified clinics across 3,142 counties, scraped 132 clinic pricing pages, and collected 658 practitioner survey responses. This snapshot reflects our multi-source methodology.
Treatment-resistant depression — typically defined as failure on two or more antidepressant trials — is the FDA-approved indication for Spravato and the most common clinical qualifier for ketamine therapy insurance coverage. Source: HealingMaps 2026 Ketamine Clinic Intelligence Report — drawn from 23,496 patient inquiries and 132 clinic website analyses.
This question is matched to the conditions Ketamine of Philadelphia treats. Editorial responses are HealingMaps-authored, grounded in our 2026 Ketamine Clinic Intelligence Report.
Ketamine of Philadelphia treats depression via IV ketamine (off-label, evidence-based). Insurance coverage is rare for IV/KAP — most patients pay out of pocket. TRD is typically defined as two or more prior antidepressant trials without sufficient response — patients meeting that bar are best candidates here.
Leave a Reply